JP2011512364A - 治療用ペプチド - Google Patents

治療用ペプチド Download PDF

Info

Publication number
JP2011512364A
JP2011512364A JP2010547006A JP2010547006A JP2011512364A JP 2011512364 A JP2011512364 A JP 2011512364A JP 2010547006 A JP2010547006 A JP 2010547006A JP 2010547006 A JP2010547006 A JP 2010547006A JP 2011512364 A JP2011512364 A JP 2011512364A
Authority
JP
Japan
Prior art keywords
dendrimer
amino acid
polypeptide
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010547006A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011512364A5 (cg-RX-API-DMAC10.html
Inventor
ヴァレンタイン アグレッツ、マイケル
Original Assignee
インター−ケイ ピーティーワイ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008900848A external-priority patent/AU2008900848A0/en
Application filed by インター−ケイ ピーティーワイ リミテッド filed Critical インター−ケイ ピーティーワイ リミテッド
Publication of JP2011512364A publication Critical patent/JP2011512364A/ja
Publication of JP2011512364A5 publication Critical patent/JP2011512364A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010547006A 2008-02-22 2009-02-23 治療用ペプチド Pending JP2011512364A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2008900848A AU2008900848A0 (en) 2008-02-22 Therapeutic peptides
PCT/AU2009/000201 WO2009103127A1 (en) 2008-02-22 2009-02-23 Therapeutic peptides

Publications (2)

Publication Number Publication Date
JP2011512364A true JP2011512364A (ja) 2011-04-21
JP2011512364A5 JP2011512364A5 (cg-RX-API-DMAC10.html) 2013-05-02

Family

ID=40985007

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010547006A Pending JP2011512364A (ja) 2008-02-22 2009-02-23 治療用ペプチド

Country Status (5)

Country Link
US (1) US20110105408A1 (cg-RX-API-DMAC10.html)
EP (1) EP2254901A4 (cg-RX-API-DMAC10.html)
JP (1) JP2011512364A (cg-RX-API-DMAC10.html)
AU (1) AU2009217237A1 (cg-RX-API-DMAC10.html)
WO (1) WO2009103127A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010215086A1 (en) * 2009-02-23 2011-09-08 Inter-K Pty Limited Inhibition of multiple cell activation pathways
EP3228714B1 (en) 2010-12-14 2019-03-27 Stichting Katholieke Universiteit Chemiluminescence-based haemostasis assay
CN104271590B (zh) * 2012-01-24 2018-06-05 Inter-K私人有限公司 用于癌治疗的肽剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023476A1 (en) * 1998-10-16 2000-04-27 Otsuka Pharmaceutical Co., Ltd. Neovascular-specific peptides
WO2005037308A1 (en) * 2003-10-17 2005-04-28 Inter-K Pty Limited Methods and agents for the treatment of cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177263A (en) * 1972-02-28 1979-12-04 Research Corporation Anti-animal tumor method
US5962643A (en) * 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
US6514745B1 (en) * 1993-07-19 2003-02-04 The Regents Of The University Of California Oncoprotein protein kinase
US5807746A (en) * 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
US6495518B1 (en) * 1994-06-13 2002-12-17 Vanderbilt University Method for importing biologically active molecules into cells
US5877282A (en) * 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
US6495514B1 (en) * 1998-01-21 2002-12-17 Mercer University Method for reducing inflammation and inducing an analgesic effect and compounds thereof
US6248558B1 (en) * 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
ATE385503T1 (de) * 1999-06-28 2008-02-15 Inter K Pty Ltd Verfahren zur modulierung von integrin- vermittelter zellaktivitaet und hierfuer geeignete reagenzien
US6312956B1 (en) * 1999-10-01 2001-11-06 Vanderbilt University Nuclear targeted peptide nucleic acid oligomer
US6471968B1 (en) * 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
AUPR230500A0 (en) * 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
US20060257359A1 (en) * 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
US20060204443A1 (en) * 2005-03-11 2006-09-14 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for tumor treatment using dendrimer conjugates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023476A1 (en) * 1998-10-16 2000-04-27 Otsuka Pharmaceutical Co., Ltd. Neovascular-specific peptides
WO2005037308A1 (en) * 2003-10-17 2005-04-28 Inter-K Pty Limited Methods and agents for the treatment of cancer

Also Published As

Publication number Publication date
AU2009217237A1 (en) 2009-08-27
EP2254901A1 (en) 2010-12-01
WO2009103127A1 (en) 2009-08-27
EP2254901A4 (en) 2012-02-22
US20110105408A1 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
AU2008273813B2 (en) Bioactive peptides and method of using same
IL223678A (en) Immunosuppressive Modulation Compounds
US9757473B2 (en) Cell-penetrating peptide and conjugate comprising same
CN102470156A (zh) 选择性作用于αvβ3整合素并缀合人血清白蛋白(HSA)变体的多肽及其药学用途
CN104271590A (zh) 用于癌治疗的肽剂
US20120277161A1 (en) Inhibition of multiple cell activation pathways
WO2018166119A1 (zh) 一种多肽或其衍生物及其在制备治疗肿瘤的药物中的应用
US11033609B2 (en) Cyclic acetylcholinesterase C-terminal peptide in the treatment or prevention of cancer or metastasis
US9765113B2 (en) Methods and agents for the treatment of cancer
JP2012518602A (ja) 複数の細胞活性化経路の阻害
US20110105408A1 (en) Therapeutic peptides
US10907212B2 (en) Inhibitors of cell adhesion
CA3168943A1 (en) Ligand-mediated delivery of therapeutic proteins and the uses thereof
KR101721733B1 (ko) 혈관신생촉진용 펩타이드 및 이의 용도
WO2018109771A1 (en) Fusion proteins for treatment of cancer
WO2021098996A1 (en) Oligopeptides that inhibit angiogenesis and vascular function
WO2016097753A1 (en) Cyclic acetylcholinesterase c-terminal peptide in the treatment or prevention of cancer or metastasis
CN111333699A (zh) 一种多肽或其衍生物及其在制备防治肿瘤的药物中的应用
US11541101B1 (en) LEMD3 antagonizes TGF-beta-driven Smad2/3 transcription in a stiffness-dependent fashion in both the nucleus and cytosol

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130620

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A072

Effective date: 20130827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140213

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140314

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140819